Secondary leukemia after treatment with paclitaxel and carboplatin in a patient with recurrent ovarian cancer

International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
H T SeeJ Kavanagh

Abstract

The occurrence of myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) has been reported after treatment with cytotoxic alkylating agent-based chemotherapy for solid tumors. We report a patient with metastatic ovarian carcinoma treated with carboplatin and paclitaxel, who developed secondary acute erythroid leukemia. The overall survival of patients with stage III and IV ovarian cancer has increased in the past decade. Monitoring of the long-term outcome of paclitaxel- and platinum-based regimens is warranted, particularly with regard to monitoring the development of secondary MDS and/or AML. The incidence and outcome of secondary leukemia in the setting of active ovarian carcinoma is reviewed.

References

Nov 27, 1985·Biochemical and Biophysical Research Communications·J L ButourJ P Macquet
Apr 1, 1996·Hematology/oncology Clinics of North America·M J Thirman, R A Larson
Feb 4, 1999·The New England Journal of Medicine·L B TravisM Stovall
May 30, 2001·Leukemia & Lymphoma·G LeoneL Pagano
Aug 8, 2001·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·E Pujade-LauraineJ P Lotz
Jul 30, 2002·Leukemia·S ParkF Dreyfus
Dec 3, 2004·Cancer Investigation·Tate Thigpen

❮ Previous
Next ❯

Citations

Jan 26, 2008·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·S YeasminK Miyazaki
Aug 12, 2009·Nihon Hinyōkika Gakkai zasshi. The japanese journal of urology·Kazuyuki NumakuraNaoto Takahashi
Oct 22, 2014·Indian Journal of Hematology & Blood Transfusion : an Official Journal of Indian Society of Hematology and Blood Transfusion·S VanajakshiK Kshitija
Apr 9, 2016·Case Reports in Oncological Medicine·Udit Bhaskar BhatnagarJill Moormeier
Aug 19, 2009·American Journal of Clinical Pathology·Magdalena Czader, Attilio Orazi
Jan 11, 2014·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·Takako ShimadaKeisuke Kodama
Feb 3, 2007·International Journal of Cancer. Journal International Du Cancer·Annika RiskaPaul Brennan
Jan 29, 2019·Frontiers in Cell and Developmental Biology·Weimei RuanUttam Surana
Nov 30, 2018·Chemical Reviews·Bernhard EnglingerWalter Berger

❮ Previous
Next ❯

Related Concepts

Related Feeds

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.